中文名 | (2S,3R,4R,5S,6R)-2-(4-氯-3-(4-乙氧基芐基)苯基)-6-(甲基硫代)四氫-2H-吡喃-3,4,5-三醇 |
---|---|
英文名 | (2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-methylsulfanyloxane-3,4,5-triol |
中文別名 | 索格列凈 |
英文別名 | 更多 |
描述 | LX-4211是SGLT1/2抑制劑,是抗糖尿病劑。 |
---|---|
相關(guān)類別 | 信號通路 >> 跨膜轉(zhuǎn)運(yùn) >> SGLT 研究領(lǐng)域 >> 代謝疾病 |
參考文獻(xiàn) | [1]. Zambrowicz B, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012 Aug;92(2):158-69. [2]. Powell DR, et al. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. J Pharmacol Exp Ther. 2013 May;345(2):250-9. |
密度 | 1.4±0.1 g/cm3 |
---|---|
沸點(diǎn) | 607.9±55.0 °C at 760 mmHg |
分子式 | C21H25ClO5S |
分子量 | 424.938 |
閃點(diǎn) | 321.4±31.5 °C |
精確質(zhì)量 | 424.111115 |
PSA | 104.45000 |
LogP | 5.63 |
蒸汽壓 | 0.0±1.8 mmHg at 25°C |
折射率 | 1.642 |
sotagliflozin |
LP-802034 |
(2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-methylsulfanyl-tetrahydro-pyran-3,4,5-triol |
β-L-Xylopyranoside, methyl 5-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-thio-, (5S)- |
LX-4211 |
(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol |
LX4211 |
CS-1069 |
LX 4211 |
Methyl (5S)-5-[4-chloro-3-(4-ethoxybenzyl)phenyl]-1-thio-β-L-xylopyranoside |
UNII-6B4ZBS263Y |